View by Specialty

Headline News

View more

Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara

March 21, 2025
2 min read
Save

Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara

Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous induction options for the treatment of moderately to severely active Crohn’s disease, Johnson & Johnson reported.

View more Headline News
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails

Resources

View more

AI in Medicine

Psychedelics & Alternative Therapies

View more Resources
View more Meeting News
View meeting calendar

Podcasts

View more
Gastroenterology, Hepatology
February 27, 2025
47 min listen

The Next Generation of GI with Prateek Sharma, MD

Gastroenterology, Hepatology
January 22, 2025
45 min listen

Living the American Dream with Maria Abreu, MD

View more Podcasts

Blogs & Columns

View more

The Rome - Healio Gastro Psych Blog brings expert opinion from the field of psychogastroenterology to our readers.

Edward V. Loftus Jr.

Editorials

with Edward V. Loftus Jr., MD

Opinions on important issues that affect gastroenterology and hepatology practice.

View more Blogs & Columns